Topical vs. traditional therapies: What’s really working for vitiligo?

Written by Healthcasts Team | Mar 20, 2026 1:16:57 PM

Nonsegmental vitiligo has long challenged dermatologists, with traditional therapies like corticosteroids and calcineurin inhibitors offering modest results and requiring ongoing maintenance.

In recent years, JAK inhibitors have emerged as a promising alternative, but questions remain about how they compare in efficacy, speed of repigmentation, and long-term disease control.

On Healthcasts, dermatologists shared their experiences using JAK inhibitors alongside—or in place of—traditional therapies, providing a window into early outcomes, patient responses, and practical considerations for treatment planning.

Have you used JAK inhibitors to treat vitiligo? L og in or sign up to share your experience and view the consensus summary.

Post:

JAK inhibitors have recently emerged as a targeted therapy for vitiligo. Their growing use is prompting clinicians to reconsider treatment algorithms for moderate to severe disease.

Questions for consult

1. In patients with nonsegmental vitiligo, how do topical or systemic JAK inhibitors compare with traditional therapies in achieving repigmentation and maintaining long-term disease control?

Comments

Key takeaways about treating vitiligo with JAK inhibitors:

JAK inhibitors often provide more consistent repigmentation
Both topical and systemic JAK inhibitors generally achieve better repigmentation than traditional therapies, particularly when combined with phototherapy, offering a more targeted approach to treating nonsegmental vitiligo.
Partial repigmentation and maintenance remain important considerations
While JAK inhibitors can be more effective, clinicians say that results may be gradual and incomplete. Long-term disease control often requires ongoing therapy, similar to traditional treatments, to sustain repigmentation.
Safety, data, and patient enthusiasm are shaping adoption
Topical JAK inhibitors are FDA-approved and supported by clinical trials, making them a safer, studied alternative to older therapies. Early experiences suggest patients are optimistic about outcomes, but clinicians note that long-term efficacy and systemic options are still under investigation.

Dermatology

"I find topical ruxolitinib or systemic JAK inhibitors often achieve more consistent repigmentation than corticosteroids or calcineurin inhibitors, especially when combined with phototherapy for sustained control."

Dermatology

"They are generally better than traditional therapies as far as efficacy, but I often combine them with traditional therapies to push the efficacy. Notwithstanding my opinion that they are better, they still are slow to work and often imperfectly repigment the affected areas—partial repigmentation is sometimes the best that can be achieved."

Dermatology

"Because traditional therapies are mostly nonspecific, they offer a unique alternative that seems very beneficial in many cases. Long-term control is a challenging issue as it may require chronic therapy, and it certainly does not work in every situation."

Dermatology

"This is a rather recent development for me in the treatment of nonsegmental vitiligo, and I have only limited short-term experience. But from early indications, I am seeing rather acceptable results. Patients seem to be quite excited by the early success and in some cases have come to the office asking for the treatment."

Dermatology

"Good clinical data and FDA approval of topical JAKS Opzelura for vitiligo, but it may take 6 months of repigmentation and need to maintain treatment to maintain results. Traditional therapies require maintenance as well, but are less safe and not studied in large-scale trials. Systemic JAKs are being studied but likely will be more effective than traditional, but will, like all of the drugs, require maintenance Rx."

Do you prefer traditional therapies or JAK inhibitors to treat patients presenting with vitiligo? Visit the full post on Healthcasts to share your opinion and read other comments from the community.

View full post